These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 11705884)

  • 1. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H; Nan L; Yu D; Agrawal S; Zhang R
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
    Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
    Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
    Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
    Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 oncogene as a target for cancer therapy: An antisense approach.
    Wang H; Zeng X; Oliver P; Le LP; Chen J; Chen L; Zhou W; Agrawal S; Zhang R
    Int J Oncol; 1999 Oct; 15(4):653-60. PubMed ID: 10493945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
    Zhang Z; Wang H; Prasad G; Li M; Yu D; Bonner JA; Agrawal S; Zhang R
    Clin Cancer Res; 2004 Feb; 10(4):1263-73. PubMed ID: 14977824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
    Xiong J; Yang Q; Li J; Zhou S
    Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Oliver P; Zhang Z; Agrawal S; Zhang R
    Ann N Y Acad Sci; 2003 Dec; 1002():217-35. PubMed ID: 14751837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.
    Prasad G; Wang H; Agrawal S; Zhang R
    Anticancer Res; 2002; 22(1A):107-16. PubMed ID: 12017271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
    Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.
    Wang H; Hang J; Shi Z; Li M; Yu D; Kandimalla ER; Agrawal S; Zhang R
    Int J Oncol; 2002 Jul; 21(1):73-80. PubMed ID: 12063552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketoconazole potentiates the antitumor effects of nocodazole: In vivo therapy for human tumor xenografts in nude mice.
    Wang YJ; Jeng JH; Chen RJ; Tseng H; Chen LC; Liang YC; Lin CH; Chen CH; Chu JS; Ho WL; Ho YS
    Mol Carcinog; 2002 Aug; 34(4):199-210. PubMed ID: 12203371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.
    Liu W; Zhang R
    Int J Oncol; 1998 Apr; 12(4):793-804. PubMed ID: 9499438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
    Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
    Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemosensitization by antisense oligonucleotides targeting MDM2.
    Bianco R; Ciardiello F; Tortora G
    Curr Cancer Drug Targets; 2005 Feb; 5(1):51-6. PubMed ID: 15720189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms.
    Zhang R; Wang H; Agrawal S
    Curr Cancer Drug Targets; 2005 Feb; 5(1):43-9. PubMed ID: 15720188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
    Zhang Z; Li M; Wang H; Agrawal S; Zhang R
    Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11636-41. PubMed ID: 13130078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
    Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer.
    Tortora G; Caputo R; Damiano V; Bianco R; Chen J; Agrawal S; Bianco AR; Ciardiello F
    Int J Cancer; 2000 Dec; 88(5):804-9. PubMed ID: 11072252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel MDM2 p53-independent functions identified through RNA silencing technologies.
    Zhang Z; Wang H; Li M; Rayburn E; Agrawal S; Zhang R
    Ann N Y Acad Sci; 2005 Nov; 1058():205-14. PubMed ID: 16394138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.